Vedolizumab biosimilar (Polpharma Biologics)

维得利珠单抗生物类似药 (Polpharma Biologics)

Report date: 2025/03/07 17:33:35

Base Information

Drug NameVedolizumab biosimilar (Polpharma Biologics)
Drug Alias NamePB-016
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionIntegrin alpha-4/beta-7 antagonistsMucosal addressin cell adhesion molecule-1 inhibitors
TargetsIntegrin alpha-4/beta-7Mucosal addressin cell adhesion molecule-1
Therapy Area/IndicationsCrohn DiseasePouchitisColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandGeorgia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPolpharma Biologics Sa
China Registration ClassN/A

Develop Information

Active CompaniesPolpharma Biologics Sa
Inactive CompaniesN/A
Active IndicationsCrohn DiseasePouchitisColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A